JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Terazosin is an antagonist of α1-adrenergic receptor [1].
Terazosin is a long acting and selective α1-adrenergic-antagonist drug. The major use of it is the treatment for benign prostatic hyperplasia since it can relax the prostatic smooth muscle. Terazosin is proved to be a safe and effective treatment and has few adverse effects [1].
Besiedes, terazosin is also used to treat for hypertension. It is found to significantly decrease blood pressure in patients with uncomplicated hypertension. It is also found to effect blood lipids beneficially. Terazosin modestly lowers blood total cholesterol, low density lipoprotein cholesterol and triglycerides as well as increases high density lipoprotein. The beneficial effects make terazosin more potent to prevent coronary heart disease [2].
References:[1] Lepor H, Williford W O, Barry M J, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New England Journal of Medicine, 1996, 335(8): 533-540.[2] Grimm R H. alpha 1-antagonists in the treatment of hypertension. Hypertension, 1989, 13(5 Suppl): I131.